ATE545429T1 - Modulation der neurotrophinaktivität;screeningsverfahren - Google Patents

Modulation der neurotrophinaktivität;screeningsverfahren

Info

Publication number
ATE545429T1
ATE545429T1 AT07118012T AT07118012T ATE545429T1 AT E545429 T1 ATE545429 T1 AT E545429T1 AT 07118012 T AT07118012 T AT 07118012T AT 07118012 T AT07118012 T AT 07118012T AT E545429 T1 ATE545429 T1 AT E545429T1
Authority
AT
Austria
Prior art keywords
methods
neurotrophin
modulation
modulating
activity
Prior art date
Application number
AT07118012T
Other languages
English (en)
Inventor
Anders Nykjer
Claus Munck Petersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of ATE545429T1 publication Critical patent/ATE545429T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
AT07118012T 2002-12-20 2003-12-19 Modulation der neurotrophinaktivität;screeningsverfahren ATE545429T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200201977 2002-12-20

Publications (1)

Publication Number Publication Date
ATE545429T1 true ATE545429T1 (de) 2012-03-15

Family

ID=32668626

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07118012T ATE545429T1 (de) 2002-12-20 2003-12-19 Modulation der neurotrophinaktivität;screeningsverfahren

Country Status (7)

Country Link
US (5) US8066997B2 (de)
EP (2) EP1891966B1 (de)
AT (1) ATE545429T1 (de)
AU (1) AU2003287930A1 (de)
DK (1) DK1891966T3 (de)
ES (1) ES2380055T3 (de)
WO (1) WO2004056385A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029624A1 (ja) * 2002-09-24 2004-04-08 Masaomi Iyo 摂食障害の診断薬および検定方法
EP1891966B1 (de) 2002-12-20 2012-02-15 H. Lundbeck A/S Modulation der Neurotrophinaktivität;Screeningsverfahren
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US8288354B2 (en) 2005-12-28 2012-10-16 The Scripps Research Institute Natural antisense and non-coding RNA transcripts as drug targets
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
EP1840133A1 (de) * 2006-03-29 2007-10-03 Global Biotech Development Corp. Ltd. Neue immunomodulierende Oligopeptide
DK3225251T3 (da) 2006-12-21 2020-03-16 H Lundbeck As Modulering af pro-neurotrofinaktivitet
EP2077278A1 (de) 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptid abgeleitet von Neurotensin-Rezeptor 3 und Anwendung zur Behandlung von psychiatrischen Erkrankungen
US8377701B2 (en) 2008-04-27 2013-02-19 H. Lundbeck A/S Specific ligands to sortilin
US9084745B2 (en) 2008-05-22 2015-07-21 H. Lundback A/S Modulation of the Vps10p-domain for the treatment of cardiovascular disease
US20160359907A1 (en) * 2015-06-02 2016-12-08 Vmware, Inc. Automatically auditing virtual machines for security hardening compliance
EP2732823B1 (de) * 2008-06-25 2019-08-07 H. Lundbeck A/S Modulation des TrpV: Vps10p-Domänen-Rezeptorsystem zur Behandlung von Schmerzen
US20100061981A1 (en) * 2008-08-15 2010-03-11 The Salk Institute For Biological Studies p75NTR MEDIATES EPHRIN-A REVERSE SIGNALING
US20120039865A1 (en) * 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
WO2010042728A1 (en) * 2008-10-08 2010-04-15 Cornell University Small molecule modulators of prongf uptake
US8447409B2 (en) * 2008-10-15 2013-05-21 Cochlear Limited Electroneural interface for a medical implant
EP2379593A2 (de) * 2008-12-19 2011-10-26 H. Lundbeck A/S Modulation der vps-10-domänenrezeptorfamilie zur behandlung von geistes- und verhaltensstörungen
DK2448970T3 (da) 2009-05-04 2014-10-06 Abbvie Res B V Antistoffer mod nervevækstfaktor (ngf) med forbedret in vivo-stabilitet
EP2483406A2 (de) 2009-09-30 2012-08-08 President and Fellows of Harvard College Verfahren zur autophagie-modulation durch modulation autophagie-hemmender genprodukte
WO2011157275A1 (en) * 2010-06-14 2011-12-22 H. Lundbeck A/S Modulation of the interaction between sorla and gdnf-family ligand receptors
US20130115222A1 (en) * 2010-06-15 2013-05-09 Cornell University Methods of limiting microvascular damage following acute myocardial ischemia
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
EP3434691A1 (de) 2010-12-01 2019-01-30 AlderBio Holdings LLC Anti-ngf-zusammensetzengen und ihre verwendung
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
TR201815503T4 (tr) 2012-03-15 2018-11-21 Curna Inc Beyin kaynaklı nörotrofik faktör (bknf) ile ilişkili hastalıkların doğal antisens transkriptinin bknf'ye inhibisyonu ile muamelesi.
ES2894852T3 (es) 2012-06-06 2022-02-16 Zoetis Services Llc Anticuerpos anti-NGF caninizados y métodos de los mismos
CN104774264B (zh) * 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
JP6640725B2 (ja) 2014-01-27 2020-02-05 セントレ ナショナル デ ラ レチャーチェ シャーティフィック ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す
JP6999421B2 (ja) 2015-04-07 2022-02-04 アレクトル エルエルシー 抗ソルチリン抗体及びその使用方法
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
WO2017101956A1 (en) * 2015-12-18 2017-06-22 Aarhus Universitet SorCS PEPTIDES AND USES THEREOF
US20190231787A1 (en) * 2016-08-25 2019-08-01 Pharmatrophix, Inc. Methods and compounds for treating alcohol use disorders and associated diseases
FR3057267A1 (fr) * 2016-10-11 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - Procede de diagnostic/determination de l'efficacite de traitement de la depression
FR3057266B1 (fr) * 2016-10-11 2021-05-21 Centre Nat Rech Scient Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
PE20210186A1 (es) 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso
EP4025258A4 (de) * 2019-09-03 2023-09-06 University of Cincinnati Verfahren und zusammensetzungen zur behandlung von als
EP4192844A1 (de) * 2020-08-06 2023-06-14 Aarhus Universitet Cyclische peptide und verwendungen davon
WO2023152229A1 (en) 2022-02-09 2023-08-17 Teitur Trophics Aps Novel peptides

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1130192A (en) * 1914-01-19 1915-03-02 Erik Oeman Process of producing sulfite cellulose.
US5604202A (en) * 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
JPH07505124A (ja) * 1991-11-08 1995-06-08 ザ ユニバーシティ オブ サザン カリフォルニア ニューロトロフィン活性増強のためのｋ−２５２化合物を含む組成物
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US6291247B1 (en) * 1994-05-11 2001-09-18 Queen's University At Kingston Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
US5728803A (en) * 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
GB9608335D0 (en) * 1996-04-23 1996-06-26 Univ Kingston Method of enhancing ngf-mediated neurite growth with low molecular weight analoues of p.75 ngfr 367-379
AU7214998A (en) * 1997-04-11 1998-11-11 Regents Of The University Of California, The Ngf for the prevention of demyelination in the nervous system
ATE257514T1 (de) 1998-10-09 2004-01-15 Scil Proteins Gmbh Verfahren zur gewinnung von aktivem beta-ngf
IT1305294B1 (it) * 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
SE9904863D0 (sv) * 1999-12-30 1999-12-30 Medscand Medical Ab New use
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
AU2002259305A1 (en) 2001-05-25 2002-12-09 Cornell Research Foundation, Inc. High affinity ligand for p75 neurotrophin receptor
EP1891966B1 (de) 2002-12-20 2012-02-15 H. Lundbeck A/S Modulation der Neurotrophinaktivität;Screeningsverfahren

Also Published As

Publication number Publication date
AU2003287930A8 (en) 2004-07-14
EP1891966B1 (de) 2012-02-15
US20170158766A1 (en) 2017-06-08
US8815808B2 (en) 2014-08-26
EP1589988A2 (de) 2005-11-02
US20150232565A1 (en) 2015-08-20
WO2004056385A3 (en) 2004-11-11
WO2004056385A2 (en) 2004-07-08
DK1891966T3 (da) 2012-04-02
EP1891966A1 (de) 2008-02-27
ES2380055T3 (es) 2012-05-08
AU2003287930A1 (en) 2004-07-14
US20130164297A1 (en) 2013-06-27
US20120082671A1 (en) 2012-04-05
US9605073B2 (en) 2017-03-28
US20070264195A1 (en) 2007-11-15
US8066997B2 (en) 2011-11-29
US8986690B2 (en) 2015-03-24

Similar Documents

Publication Publication Date Title
ATE545429T1 (de) Modulation der neurotrophinaktivität;screeningsverfahren
Aguayo et al. Degenerative and regenerative responses of injured neurons in the central nervous system of adult mammals
DE69939950D1 (de) Verwendung von neuregulin zur beeinflussung der herzmuskelfunktion
NZ335207A (en) Process to isolate recombinant human neurotrophin using hydrophobic chromatography resin
ATE228003T1 (de) Verwendung von cntf (ciliary neurotrophic factor) rezeptoraktivatoren fur behandlung von fettleibigkeit
DE69527525D1 (de) Verfahren zur Schachtelung von Datenrahmen, Übertragungsfehlerkorrekturanordnung und Modulator damit
DE69736976D1 (de) Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden
DE69525860D1 (de) Herstellung von zeolithen unter verwendung von organischem templat und amin
DE69631588D1 (de) Benzolpiperidine/pyrrolidine zur verbesserung synaptischer reaktion
Unsicker et al. Co-activation of TGF-ss and cytokine signaling pathways are required for neurotrophic functions
DE69832730D1 (de) Methode zur behandlung von dopaminergen und gaba-nergen störungen
ATE86097T1 (de) Mittel zur faerbung von haaren und anwendung desselben.
DE60031951D1 (de) Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen
DE69637185D1 (de) Isolierte Stromazellen und Methoden zu deren Verwendung
DE59101232D1 (de) Verfahren und Mittel zur Herstellung von Bohrungen.
DK1427830T3 (da) Bv8-nukleinsyrer og -polypeptider med mitogen aktivitet
DE69325452D1 (de) Verfahren zur herstellung von (s)-3-amino-1-substituiert-pirrolidine
DK0593516T3 (da) Fremgangsmåder til behandling af motorneuronsygdomme ved anvendelse af medlemmer af BDNF/NT-3/NGF-molekylfamilien
DE50111147D1 (de) Bioartifizielle, primär vaskularisierte Gewebematrix und bioartifizielles, primär vaskularisiertes Gewebe
ATE357238T1 (de) Verfahren zur herstellung von selbstinduzierender synthase
ATE210126T1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
DE68916099D1 (de) Vorrichtungen und Mittel zur auswendigen Anwendung von Substanzen an Tieren.
DE59308366D1 (de) Verfahren zur Aufhellung von Isocyanurat- und Uretdiongruppen enthaltenden Polyisocyanaten
WO1998015172A3 (en) Transgenic or mutated animal as model for a neuron deficit
ES2172596T3 (es) Cultivos neuronales.